# Guardant Health Inc. (GH)

Source: https://www.quantisnow.com/company/GH
Generated: 2026-11-12T13:30:02.726Z

- Ticker: GH
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical Specialities
- IPO year: 2018
- SEC CIK: 0001576280
- Website: guardanthealth.com

## About

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

## Latest GH news and filings

- 2026-11-12 06:09 UTC [Guardant Health Prices $500 Million Convertible Senior Notes Offering](https://www.quantisnow.com/insight/guardant-health-prices-500-million-convertible-senior-notes-offering-6785557)
- 2026-11-11 21:17 UTC [Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032](https://www.quantisnow.com/insight/guardant-health-announces-proposed-5000-million-offering-of-convertible-senior-6785492)
- 2026-11-11 13:46 UTC [Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid](https://www.quantisnow.com/insight/guardant-health-introduces-new-epigenomic-applications-providing-deeper-insights-for-6785306)
- 2026-11-10 21:05 UTC [PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases](https://www.quantisnow.com/insight/precision-study-published-in-esmo-open-highlights-utility-of-guardant360-6783867)
- 2026-11-09 21:30 UTC [Conference Announcement] [Guardant Health to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/guardant-health-to-participate-in-upcoming-investor-conferences-6781663)
- 2026-11-05 22:13 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Guardant Health Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-guardant-health-inc-6777348)
- 2026-11-05 21:08 UTC [SEC Form 8-K] [Guardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/guardant-health-inc-filed-sec-form-8-k-results-of-operations-6776371)
- 2026-11-05 21:05 UTC [Earnings] [Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance](https://www.quantisnow.com/insight/guardant-health-reports-third-quarter-2026-financial-results-and-increases-6776148)
- 2026-11-05 18:19 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Guardant Health Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-guardant-health-inc-6775549)
- 2026-11-05 12:30 UTC [TwinStrand Biosciences Announces USPTO Confirmation of Patentability of Core Duplex Sequencing Patent](https://www.quantisnow.com/insight/twinstrand-biosciences-announces-uspto-confirmation-of-patentability-of-core-duplex-6774671)
- 2026-11-03 21:40 UTC [SEC Form 8-K] [Guardant Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/guardant-health-inc-filed-sec-form-8-k-leadership-update-financial-6770219)
- 2026-11-03 21:30 UTC [Leadership Update] [Kevin Sayer Joins Guardant Health Board of Directors](https://www.quantisnow.com/insight/kevin-sayer-joins-guardant-health-board-of-directors-6770060)
- 2026-11-03 13:19 UTC [SEC Form 8-K] [Guardant Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/guardant-health-inc-filed-sec-form-8-k-leadership-update-financial-6768683)
- 2026-11-03 13:05 UTC [Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test](https://www.quantisnow.com/insight/guardant-health-wins-2026-prix-galien-usa-award-for-best-6768511)
- 2026-10-29 12:05 UTC [Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians](https://www.quantisnow.com/insight/guardant-health-applauds-new-law-ensuring-access-to-colorectal-cancer-6762693)
- 2026-10-23 11:34 UTC [Analyst Coverage Initiated] [Roth Capital initiated coverage on Guardant Health with a new price target](https://www.quantisnow.com/insight/roth-capital-initiated-coverage-on-guardant-health-with-a-new-6755832)
- 2026-10-22 20:47 UTC [SEC Form 4] [SEC Form 4 filed by Guardant Health Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-guardant-health-inc-6755438)
- 2026-10-20 13:02 UTC [Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026](https://www.quantisnow.com/insight/guardant-health-highlights-broad-liquid-biopsy-research-portfolio-at-esmo-6751739)
- 2026-10-19 21:02 UTC [SEC Form 4] [SEC Form 4 filed by Guardant Health Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-guardant-health-inc-6750937)
- 2026-10-19 21:02 UTC [SEC Form 4] [Director Tariq Musa sold $19,242 worth of shares (116 units at $165.88) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-tariq-musa-sold-19242-worth-of-shares-116-units-6750933)
- 2026-10-15 22:02 UTC [SEC Form 4] [Director Azar Alex M Ii sold $11,032 worth of shares (69 units at $159.89) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-azar-alex-m-ii-sold-11032-worth-of-shares-6748440)
- 2026-10-15 20:01 UTC [TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent](https://www.quantisnow.com/insight/twinstrand-biosciences-announces-second-us-patent-trial-and-appeal-board-6747921)
- 2026-10-15 12:05 UTC [Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests](https://www.quantisnow.com/insight/guardant-health-shield-blood-test-demonstrates-leading-screening-adherence-and-6747355)
- 2026-10-14 20:01 UTC [SEC Form 144] [SEC Form 144 filed by Guardant Health Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-guardant-health-inc-6746520)
- 2026-10-13 21:10 UTC [SEC Form 4] [SEC Form 4 filed by Guardant Health Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-guardant-health-inc-6745428)
- 2026-10-08 20:12 UTC [Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer](https://www.quantisnow.com/insight/guardant-health-announces-approval-in-europe-of-guardant360-cdx-as-6741786)
- 2026-10-08 20:05 UTC [Earnings Date] [Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026](https://www.quantisnow.com/insight/guardant-health-to-report-third-quarter-2026-financial-results-on-6741729)
- 2026-10-05 15:27 UTC [Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma](https://www.quantisnow.com/insight/guardant-health-cosmos-study-published-in-cancer-research-communications-validates-6736378)
- 2026-10-02 21:01 UTC [SEC Form 4] [Chief Legal Officer Saia John G. converted options into 7,063 shares and covered exercise/tax liability with 3,706 shares, increasing direct ownership by 9% to 42,348 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-legal-officer-saia-john-g-converted-options-into-7063-6735130)
- 2026-10-02 21:01 UTC [SEC Form 4] [Chief People Officer Monroe Terilyn J. converted options into 4,019 shares and covered exercise/tax liability with 2,098 shares, increasing direct ownership by 8% to 24,900 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-people-officer-monroe-terilyn-j-converted-options-into-4019-6735128)
- 2026-10-02 21:00 UTC [SEC Form 4] [Chief Information Officer Kalia Kumud converted options into 6,046 shares and covered exercise/tax liability with 3,067 shares, increasing direct ownership by 7% to 42,773 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/chief-information-officer-kalia-kumud-converted-options-into-6046-shares-6735118)
- 2026-10-02 21:00 UTC [SEC Form 4] [Chief Commercial Officer Freeman Chris converted options into 7,416 shares and covered exercise/tax liability with 3,143 shares, increasing direct ownership by 7% to 69,647 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-commercial-officer-freeman-chris-converted-options-into-7416-shares-6735110)
- 2026-10-02 20:59 UTC [SEC Form 4] [Chief Technology Officer Chudova Darya converted options into 8,033 shares and covered exercise/tax liability with 4,320 shares, increasing direct ownership by 5% to 74,348 units (SEC Form 4) (tax withholding)](https://www.quantisnow.com/insight/chief-technology-officer-chudova-darya-converted-options-into-8033-shares-6735091)
- 2026-10-02 20:59 UTC [SEC Form 4] [Chief Financial Officer Bell Michael Brian converted options into 7,280 shares and covered exercise/tax liability with 3,914 shares, increasing direct ownership by 6% to 55,182 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-financial-officer-bell-michael-brian-converted-options-into-7280-6735085)
- 2026-10-02 20:58 UTC [SEC Form 4] [Co-Chief Executive Officer Talasaz Amirali covered exercise/tax liability with 18,515 shares and converted options into 36,530 shares (SEC Form 4) (tax withholding)](https://www.quantisnow.com/insight/co-chief-executive-officer-talasaz-amirali-covered-exercisetax-liability-with-18515-6735084)
- 2026-10-02 20:58 UTC [SEC Form 4] [Co-Chief Executive Officer Eltoukhy Helmy converted options into 36,530 shares and covered exercise/tax liability with 18,515 shares (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/co-chief-executive-officer-eltoukhy-helmy-converted-options-into-36530-shares-6735080)
- 2026-09-22 20:33 UTC [SEC Form 4] [Director Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 10,274 units (SEC Form 4)](https://www.quantisnow.com/insight/director-mignone-roberto-converted-options-into-264-shares-increasing-direct-6723139)
- 2026-09-21 22:16 UTC [SEC Form 4] [Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 5,020 units (SEC Form 4)](https://www.quantisnow.com/insight/director-hidalgo-medina-manuel-converted-options-into-232-shares-increasing-6722091)
- 2026-09-17 21:11 UTC [SEC Form 4] [Chief Technology Officer Chudova Darya sold $1,377,364 worth of shares (7,738 units at $178.00), decreasing direct ownership by 10% to 70,635 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-technology-officer-chudova-darya-sold-1377364-worth-of-shares-6719582)
- 2026-09-17 21:09 UTC [SEC Form 4] [Director Azar Alex M Ii sold $144,550 worth of shares (826 units at $175.00), decreasing direct ownership by 50% to 825 units (SEC Form 4)](https://www.quantisnow.com/insight/director-azar-alex-m-ii-sold-144550-worth-of-shares-6719580)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GH
- Earnings history: https://www.quantisnow.com/earnings/GH
- Dividend history: https://www.quantisnow.com/dividends/GH
- Insider transactions: https://www.quantisnow.com/insiders/GH
- Options chain: https://www.quantisnow.com/options/GH
- SEC 8-K filings only: https://www.quantisnow.com/company/GH/8-k
- RSS and alerts for GH: https://www.quantisnow.com/docs/rss-feeds.md